Search

Your search keyword '"Verdegaal, Els M.E."' showing total 31 results
Start Over Author "Verdegaal, Els M.E."
31 results on '"Verdegaal, Els M.E."'

2. Figure S15 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies

Author

Groeneveldt, Christianne, primary, Kinderman, Priscilla, primary, Griffioen, Lisa, primary, Rensing, Olivia, primary, Labrie, Camilla, primary, van den Wollenberg, Diana J.M., primary, Hoeben, Rob C., primary, Coffey, Matt, primary, Loghmani, Houra, primary, Verdegaal, Els M.E., primary, Welters, Marij J.P., primary, van der Burg, Sjoerd H., primary, van Hall, Thorbald, primary, and van Montfoort, Nadine, primary

Published
2024
Full Text
View/download PDF

3. Data from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies

Author

Groeneveldt, Christianne, primary, Kinderman, Priscilla, primary, Griffioen, Lisa, primary, Rensing, Olivia, primary, Labrie, Camilla, primary, van den Wollenberg, Diana J.M., primary, Hoeben, Rob C., primary, Coffey, Matt, primary, Loghmani, Houra, primary, Verdegaal, Els M.E., primary, Welters, Marij J.P., primary, van der Burg, Sjoerd H., primary, van Hall, Thorbald, primary, and van Montfoort, Nadine, primary

Published
2024
Full Text
View/download PDF

4. Supplementary Tables S1-S3 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies

Author

Groeneveldt, Christianne, primary, Kinderman, Priscilla, primary, Griffioen, Lisa, primary, Rensing, Olivia, primary, Labrie, Camilla, primary, van den Wollenberg, Diana J.M., primary, Hoeben, Rob C., primary, Coffey, Matt, primary, Loghmani, Houra, primary, Verdegaal, Els M.E., primary, Welters, Marij J.P., primary, van der Burg, Sjoerd H., primary, van Hall, Thorbald, primary, and van Montfoort, Nadine, primary

Published
2024
Full Text
View/download PDF

5. Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies

Author

Groeneveldt, Christianne, primary, Kinderman, Priscilla, additional, Griffioen, Lisa, additional, Rensing, Olivia, additional, Labrie, Camilla, additional, van den Wollenberg, Diana J.M., additional, Hoeben, Rob C., additional, Coffey, Matt, additional, Loghmani, Houra, additional, Verdegaal, Els M.E., additional, Welters, Marij J.P., additional, van der Burg, Sjoerd H., additional, van Hall, Thorbald, additional, and van Montfoort, Nadine, additional

Published
2024
Full Text
View/download PDF

6. Supplementary Table S2 from Neoantigen Targetability in Progressive Advanced Melanoma

Author

van den Bulk, Jitske, primary, Verdegaal, Els M.E., primary, van der Ploeg, Manon, primary, Visser, Marten, primary, Nunes, Joana B., primary, de Ru, Arnoud H., primary, Tjokrodirijo, Rayman T.N., primary, Ijsselsteijn, Marieke E., primary, Janssen, Natasja I., primary, van der Breggen, Ruud, primary, de Bruin, Linda, primary, de Kok, Pita, primary, Janssen, George M.C., primary, Ruano, Dina, primary, Kapiteijn, Ellen H.W., primary, van Veelen, Peter A., primary, de Miranda, Noel F.C.C., primary, and van der Burg, Sjoerd H., primary

Published
2023
Full Text
View/download PDF

7. Supplementary Methods S1 from Neoantigen Targetability in Progressive Advanced Melanoma

Author

van den Bulk, Jitske, primary, Verdegaal, Els M.E., primary, van der Ploeg, Manon, primary, Visser, Marten, primary, Nunes, Joana B., primary, de Ru, Arnoud H., primary, Tjokrodirijo, Rayman T.N., primary, Ijsselsteijn, Marieke E., primary, Janssen, Natasja I., primary, van der Breggen, Ruud, primary, de Bruin, Linda, primary, de Kok, Pita, primary, Janssen, George M.C., primary, Ruano, Dina, primary, Kapiteijn, Ellen H.W., primary, van Veelen, Peter A., primary, de Miranda, Noel F.C.C., primary, and van der Burg, Sjoerd H., primary

Published
2023
Full Text
View/download PDF

8. Supplementary Figure S3 from Neoantigen Targetability in Progressive Advanced Melanoma

Author

van den Bulk, Jitske, primary, Verdegaal, Els M.E., primary, van der Ploeg, Manon, primary, Visser, Marten, primary, Nunes, Joana B., primary, de Ru, Arnoud H., primary, Tjokrodirijo, Rayman T.N., primary, Ijsselsteijn, Marieke E., primary, Janssen, Natasja I., primary, van der Breggen, Ruud, primary, de Bruin, Linda, primary, de Kok, Pita, primary, Janssen, George M.C., primary, Ruano, Dina, primary, Kapiteijn, Ellen H.W., primary, van Veelen, Peter A., primary, de Miranda, Noel F.C.C., primary, and van der Burg, Sjoerd H., primary

Published
2023
Full Text
View/download PDF

9. Data from Neoantigen Targetability in Progressive Advanced Melanoma

Author

van den Bulk, Jitske, primary, Verdegaal, Els M.E., primary, van der Ploeg, Manon, primary, Visser, Marten, primary, Nunes, Joana B., primary, de Ru, Arnoud H., primary, Tjokrodirijo, Rayman T.N., primary, Ijsselsteijn, Marieke E., primary, Janssen, Natasja I., primary, van der Breggen, Ruud, primary, de Bruin, Linda, primary, de Kok, Pita, primary, Janssen, George M.C., primary, Ruano, Dina, primary, Kapiteijn, Ellen H.W., primary, van Veelen, Peter A., primary, de Miranda, Noel F.C.C., primary, and van der Burg, Sjoerd H., primary

Published
2023
Full Text
View/download PDF

10. Neoantigen Targetability in Progressive Advanced Melanoma

Author

van den Bulk, Jitske, primary, Verdegaal, Els M.E., additional, van der Ploeg, Manon, additional, Visser, Marten, additional, Nunes, Joana B., additional, de Ru, Arnoud H., additional, Tjokrodirijo, Rayman T.N., additional, Ijsselsteijn, Marieke E., additional, Janssen, Natasja I., additional, van der Breggen, Ruud, additional, de Bruin, Linda, additional, de Kok, Pita, additional, Janssen, George M.C., additional, Ruano, Dina, additional, Kapiteijn, Ellen H.W., additional, van Veelen, Peter A., additional, de Miranda, Noel F.C.C., additional, and van der Burg, Sjoerd H., additional

Published
2023
Full Text
View/download PDF

11. Supplementary Figures 1 through 5 and supplementary Tables 1 through 3 from Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature

Author

Melief, Sara M., primary, Visconti, Valeria V., primary, Visser, Marten, primary, van Diepen, Merel, primary, Kapiteijn, Ellen H.W., primary, van den Berg, Joost H., primary, Haanen, John B.A.G., primary, Smit, Vincent T.H.B.M., primary, Oosting, Jan, primary, van der Burg, Sjoerd H., primary, and Verdegaal, Els M.E., primary

Published
2023
Full Text
View/download PDF

13. Data from Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature

Author

Melief, Sara M., primary, Visconti, Valeria V., primary, Visser, Marten, primary, van Diepen, Merel, primary, Kapiteijn, Ellen H.W., primary, van den Berg, Joost H., primary, Haanen, John B.A.G., primary, Smit, Vincent T.H.B.M., primary, Oosting, Jan, primary, van der Burg, Sjoerd H., primary, and Verdegaal, Els M.E., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure legends from Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature

Author

Melief, Sara M., primary, Visconti, Valeria V., primary, Visser, Marten, primary, van Diepen, Merel, primary, Kapiteijn, Ellen H.W., primary, van den Berg, Joost H., primary, Haanen, John B.A.G., primary, Smit, Vincent T.H.B.M., primary, Oosting, Jan, primary, van der Burg, Sjoerd H., primary, and Verdegaal, Els M.E., primary

Published
2023
Full Text
View/download PDF

16. Neoantigen landscape dynamics during human melanoma-T cell interactions

Author

Verdegaal, Els M.E., de Miranda, Noel F.C.C., Visser, Marten, Harryvan, Tom, van Buuren, Marit M., Andersen, Rikke S., Hadrup, Sine R., van der Minne, Caroline E., Schotte, Remko, Spits, Hergen, Haanen, John B.A.G., Kapiteijn, Ellen H.W., Schumacher, Ton N., and van der Burg, Sjoerd H.

Subjects
T cells -- Analysis, Rodents -- Research -- Health aspects, Immunotherapy -- Analysis, Tumor antigens -- Research -- Health aspects, Melanoma -- Research -- Health aspects, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

Recognition of neoantigens that are formed as a consequence of DNA damage is likely to form a major driving force behind the clinical activity of cancer immunotherapies such as T-cell checkpoint blockade and adoptive T-cell therapy (1-7). Therefore, strategies to selectively enhance T-cell reactivity against genetically defined neoantigens (1,8-11) are currently under development. In mouse models, T-cell pressure can sculpt the antigenicity of tumours, resulting in the emergence of tumours that lack defined mutant antigens (12,13). However, whether the T-cell-recognized neoantigen repertoire in human cancers is constant over time is unclear. Here we analyse the stability of neoantigen-specific T-cell responses and the antigens they recognize in two patients with stage IV melanoma treated by adoptive T-cell transfer. The T-cell-recognized neoantigens can be selectively lost from the tumour cell population, either by overall reduced expression of the genes or loss of the mutant alleles. Notably, loss of expression of T-cell-recognized neoantigens was accompanied by development of neoantigen-specific T-cell reactivity in tumour-infiltrating lymphocytes. These data demonstrate the dynamic interactions between cancer cells and T cells, which suggest that T cells mediate neoantigen immunoediting, and indicate that the therapeutic induction of broad neoantigen-specific T-cell responses should be used to avoid tumour resistance., Cytotoxic [CD8.sup.+] T cells can specifically recognize and eliminate tumours (14-16). The clinical activity of antibodies against the T-cell checkpoints CTLA-4 and PD-1 underscores the notion that in many patients [...]

Published
2016
Full Text
View/download PDF

18. Enhanced antigen cross-presentation in human colorectal cancer-associated fibroblasts through upregulation of the lysosomal protease cathepsin S

Author

MMB Research line 3a, Infection & Immunity, Harryvan, Tom J., Visser, Marten, De Bruin, Linda, Plug, Léonie, Griffioen, Lisa, Mulder, Arend, Van Veelen, Peter A., Van Der Heden Van Noort, Gerbrand J., Jongsma, Marlieke L.M., Meeuwsen, Miranda H., Wiertz, Emmanuel J.H.J., Santegoets, Saskia J., Hardwick, James C.H., Van Hall, Thorbald, Neefjes, Jacques, Van Der Burg, Sjoerd H., Hawinkels, Lukas J.A.C., Verdegaal, Els M.E., MMB Research line 3a, Infection & Immunity, Harryvan, Tom J., Visser, Marten, De Bruin, Linda, Plug, Léonie, Griffioen, Lisa, Mulder, Arend, Van Veelen, Peter A., Van Der Heden Van Noort, Gerbrand J., Jongsma, Marlieke L.M., Meeuwsen, Miranda H., Wiertz, Emmanuel J.H.J., Santegoets, Saskia J., Hardwick, James C.H., Van Hall, Thorbald, Neefjes, Jacques, Van Der Burg, Sjoerd H., Hawinkels, Lukas J.A.C., and Verdegaal, Els M.E.

Published
2022

19. High-throughput epitope discovery reveals frequent recognition of neo-antigens by [CD4.sup.+] T cells in human melanoma

Author

Linnemann, Carsten, van Buuren, Marit M., Bies, Laura, Verdegaal, Els M.E., Schotte, Remko, Calis, Jorg J.A., Behjati, Sam, Velds, Arno, Hilkmann, Henk, el Atmioui, Dris, Visser, Marten, Stratton, Michael R., Haanen, John B.A.G., Spits, Hergen, van der Burg, Sjoerd H., and Schumacher, Ton N.M.

Subjects
T cells -- Physiological aspects -- Genetic aspects -- Research, Antigenic determinants -- Physiological aspects -- Genetic aspects -- Research, Tumor antigens -- Physiological aspects -- Genetic aspects -- Research, Melanoma -- Development and progression -- Genetic aspects -- Research, Biological sciences, Health
Abstract

Tumor-specific neo-antigens that arise as a consequence of mutations (1,2) are thought to be important for the therapeutic efficacy of cancer immunotherapies (3-5). Accumulating evidence suggests that neo-antigens may be commonly recognized by intratumoral [CD8.sup.+] T cells (3-7), but it is unclear whether neoantigen-specific [CD4.sup.+] T cells also frequently reside within human tumors. In view of the accepted role of tumor-specific [CD4.sup.+] T-cell responses in tumor control (8-10), we addressed whether neo-antigen-specific [CD4.sup.+] T-cell reactivity is a common property in human melanoma., Here, we exploit oncogene-immortalized autologous B cells to measure the occurrence of [CD4.sup.+] T-cell responses against melanoma mutanomes identified by tumor exome sequencing. Using this approach, we detected neo-antigen-reactive [CD4.sup.+] [...]

Published
2015

21. Blood-based kinase activity profiling:A potential predictor of response to immune checkpoint inhibition in metastatic cancer

Author

Hurkmans, Daan P., Verdegaal, Els M.E., Hogan, Sabrina A., De Wijn, Rik, Hovestad, Lies, Van Den Heuvel, Dianne M.A., Ruijtenbeek, Rob, Welters, Marij J.P., Van Brakel, Mandy, Basak, Edwin A., Pinedo, Herbert M., Lamers, Cor H.J., Van De Werken, Harmen J.G., Groten, John P., Debets, Reno, Levesque, Mitchell P., Dummer, Reinhard, Kapiteijn, Ellen, Mathijssen, Ron H.J., Aerts, Joachim G.J.V., Van Der Burg, Sjoerd H., Hurkmans, Daan P., Verdegaal, Els M.E., Hogan, Sabrina A., De Wijn, Rik, Hovestad, Lies, Van Den Heuvel, Dianne M.A., Ruijtenbeek, Rob, Welters, Marij J.P., Van Brakel, Mandy, Basak, Edwin A., Pinedo, Herbert M., Lamers, Cor H.J., Van De Werken, Harmen J.G., Groten, John P., Debets, Reno, Levesque, Mitchell P., Dummer, Reinhard, Kapiteijn, Ellen, Mathijssen, Ron H.J., Aerts, Joachim G.J.V., and Van Der Burg, Sjoerd H.

Abstract

Background Many cancer patients do not obtain clinical benefit from immune checkpoint inhibition. Checkpoint blockade targets T cells, suggesting that tyrosine kinase activity profiling of baseline peripheral blood mononuclear cells may predict clinical outcome. Methods Here a total of 160 patients with advanced melanoma or non-small-cell lung cancer (NSCLC), treated with anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) or anti-programmed cell death 1 (anti-PD-1), were divided into five discovery and cross-validation cohorts. The kinase activity profile was generated by analyzing phosphorylation of peripheral blood mononuclear cell lysates in a microarray comprising of 144 peptides derived from sites that are substrates for protein tyrosine kinases. Binary grouping into patients with or without clinical benefit was based on Response Evaluation Criteria in Solid Tumors V.1.1. Predictive models were trained using partial least square discriminant analysis (PLS-DA), performance of the models was evaluated by estimating the correct classification rate (CCR) using cross-validation. Results The kinase phosphorylation signatures segregated responders from non-responders by differences in canonical pathways governing T-cell migration, infiltration and co-stimulation. PLS-DA resulted in a CCR of 100% and 93% in the anti-CTLA-4 and anti-PD1 melanoma discovery cohorts, respectively. Cross-validation cohorts to estimate the accuracy of the predictive models showed CCRs of 83% for anti-CTLA-4 and 78% or 68% for anti-PD-1 in melanoma or NSCLC, respectively. Conclusion Blood-based kinase activity profiling for response prediction to immune checkpoint inhibitors in melanoma and NSCLC revealed increased kinase activity in pathways associated with T-cell function and led to a classification model with a highly accurate classification rate in cross-validation groups. The predictive value of kinase activity profiling is prospectively verified in an ongoing trial.

Published
2020

22. Abstract A186: A new strategy to identify and expand tumor-reactive CD8 TILs in human solid tumors

Author

Duhen, Thomas, primary, Duhen, Rebekka, additional, Montler, Ryan, additional, Moudgil, Tarsem, additional, Bulk, Jitske van den, additional, Fox, Bernard A., additional, Chang, Shu-Ching, additional, Grunkemeier, Gary, additional, Verdegaal, Els M.E., additional, Miranda, Noel F. de, additional, Leidner, Rom, additional, Bell, Richard B., additional, and Weinberg, Andrew D., additional

Published
2019
Full Text
View/download PDF

23. Abstract B094: Successful identification of neoantigen-specific T-cell responses in low mutation burden colorectal cancers for personalized cancer vaccine development

Author

Bulk, Jitske van den, primary, Ruano, Dina, additional, Ijsselsteijn, Marieke E., additional, Visser, Marten, additional, Breggen, Ruud van der, additional, Peeters, Koen C.M.J., additional, Duhen, Thomas, additional, Duhen, Rebekka, additional, Weinberg, Andrew D, additional, Burg, Sjoerd S.H. van der, additional, Verdegaal, Els M.E., additional, and Miranda, Noel F. de, additional

Published
2019
Full Text
View/download PDF

25. Identification of non-mutated neoantigens presented by TAP-deficient tumors

Author

Marijt, Koen A., primary, Blijleven, Laura, additional, Verdegaal, Els M.E., additional, Kester, Michel G., additional, Kowalewski, Daniel J., additional, Rammensee, Hans-Georg, additional, Stevanović, Stefan, additional, Heemskerk, Mirjam H.M., additional, van der Burg, Sjoerd H., additional, and van Hall, Thorbald, additional

Published
2018
Full Text
View/download PDF

26. Blood-based multiplex kinase activity profiling as a predictive marker for clinical response to checkpoint blockade in advanced melanoma.

Author

Hurkmans, Daan, primary, Verdegaal, Els M.E., additional, Schindler, Sabrina A., additional, Basak, Edwin A., additional, van den Heuvel, Dianne M.A., additional, de Wijn, Rik, additional, Ruijtenbeek, Rob, additional, Groten, John P., additional, Dummer, Reinhard, additional, Koolen, Stijn L.W., additional, Welters, Marij J.P., additional, Mathijssen, Ron H.J., additional, Kapiteijn, Ellen, additional, Aerts, Joachim G.J.V., additional, Levesque, Mitchell P., additional, and van der Burg, Sjoerd H., additional

Published
2018
Full Text
View/download PDF

29. Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature

Author

Melief, Sara M., primary, Visconti, Valeria V., additional, Visser, Marten, additional, van Diepen, Merel, additional, Kapiteijn, Ellen H.W., additional, van den Berg, Joost H., additional, Haanen, John B.A.G., additional, Smit, Vincent T.H.B.M., additional, Oosting, Jan, additional, van der Burg, Sjoerd H., additional, and Verdegaal, Els M.E., additional

Published
2017
Full Text
View/download PDF

30. Abstract PR11: Neo-antigen landscape dynamics during human melanoma-T cell interactions

Author

Verdegaal, Els M.E., primary, Miranda, Noel de, additional, Visser, Marten, additional, Harryvan, Tom, additional, Buuren, Marit van, additional, Andersen, Rikke, additional, Hadrup, Sine, additional, Minne, Caroline van der, additional, Schotte, Remko, additional, Spits, Hergen, additional, Haanen, John, additional, Kapiteijn, Ellen, additional, Schumacher, Ton, additional, and Burg, Sjoerd H. Van Der, additional

Published
2016
Full Text
View/download PDF

31. The ABCs of Antigen Presentation by Stromal Non-Professional Antigen-Presenting Cells.

Author

Harryvan, Tom J., de Lange, Sabine, Hawinkels, Lukas J.A.C., and Verdegaal, Els M.E.

Subjects
T cells, ANTIGEN presentation, DENDRITIC cells, MAJOR histocompatibility complex, CELL physiology, STROMAL cells, ENDOTHELIAL cells
Abstract

Professional antigen-presenting cells (APCs), such as dendritic cells and macrophages, are known for their ability to present exogenous antigens to T cells. However, many other cell types, including endothelial cells, fibroblasts, and lymph node stromal cells, are also capable of presenting exogenous antigens to either CD8+ or CD4+ T cells via cross-presentation or major histocompatibility complex (MHC) class II-mediated presentation, respectively. Antigen presentation by these stromal nonprofessional APCs differentially affect T cell function, depending on the type of cells that present the antigen, as well as the local (inflammatory) micro-environment. It has been recently appreciated that nonprofessional APCs can, as such, orchestrate immunity against pathogens, tumor survival, or rejection, and aid in the progression of various auto-immune pathologies. Therefore, the interest for these nonprofessional APCs is growing as they might be an important target for enhancing various immunotherapies. In this review, the different nonprofessional APCs are discussed, as well as their functional consequences on the T cell response, with a focus on immuno-oncology. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results